Caffeine and risk of Parkinson’s disease in a large cohort of men and women

Palacios, Natalia, Gao, Xiang, McCullough, Marjorie L., Schwarzschild, Michael A., Shah, Roma, Gapstur, Susan, Ascherio, Alberto·2012·Movement Disorders
DOI 10.1002/mds.25076

Cited by (185)

Items 101–185 of 185

  1. Habitual Coffee Consumption Enhances Attention and Vigilance in Hemodialysis Patients
    Petar M. Nikić, Branislav Andrić, Biljana B. Stojimirovic, Jasna Trbojevic Stankovic, Zoran Bukumirić · 2014 · BioMed Research International
  2. Bebidas cafeínadas energizantes: efectos neurológicos y cardiovasculares
    Universidad CES, CI Manrique, Claudia Lucía Arroyave Hoyos, Universidad CES, David Andrés Galvis Pareja, Universidad CES · 2018 · IATREIA
  3. Traumatic brain injury preceding clinically diagnosed α-synucleinopathies
    Shemonti Hasan, Michelle M. Mielke, Pierpaolo Turcano, J. Eric Ahlskog, James H. Bower, Rodolfo Savica · 2020 · Neurology
  4. Perspective: Neuroregenerative Nutrition
    Dennis A. Steindler, Brent A. Reynolds · 2017 · Advances in Nutrition
  5. The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome
    Antoni Cortés, Verònica Casadó-Anguera, Estefanía Moreno, Vicent Casadó · 2019 · Advances in pharmacology
  6. Caffeine induces age-dependent increases in brain complexity and criticality during sleep
    Philipp Thölke, Maxine Arcand-Lavigne, Tarek Lajnef, Sonia Frenette, Julie Carrier, Karim Jerbi · 2025 · Communications Biology
  7. Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease
    Emmanuelle Pourcher, Philippe Huot · 2015 · Movement Disorders Clinical Practice
  8. Movement Disorders in Women
    J. Baker, Albert Y. Hung · 2017 · Seminars in Neurology
  9. Independent and Joint Associations of Tea Consumption and Smoking with Parkinson’s Disease Risk in Chinese Adults
    Jia Nie, for the China Kadoorie Biobank (CKB) Collaborative Group, Chunyu Liu, Canqing Yu, Yu Guo, Pei Pei, Ling Yang, Yiping Chen, Huaidong Du, Kaifei Zhu et al. · 2022 · Journal of Parkinson s Disease
  10. Recent Studies on Nutrition and Parkinson’s Disease Prevention: A Systematic Review
    Ann Gaba · 2015 · Open Journal of Preventive Medicine
  11. Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease
    Alexandra Kasabova-Angelova, Diana Tzankova, Javor Mitkov, Maya Georgieva, Virginia Tzankova, Alexander Zlatkov, Magdalena Kondeva-Burdina · 2018 · Current Medicinal Chemistry
  12. Chronic caffeine ingestion causes microglia activation, but not proliferation in the healthy brain
    Robert Steger, Arifa Kamal, Sarah A.F. Lutchman, Liliana Intrabartolo, Rabia Sohail, Joshua C. Brumberg · 2014 · Brain Research Bulletin
  13. A Case–Control Study of the Effects of Chimarrão (Ilex paraguariensis) and Coffee on Parkinson's Disease
    Márcio Schneider Medeiros, Artur Francisco Schumacher Schuh, Vivian Altmann, Carlos Roberto de Mello Rieder · 2021 · Frontiers in Neurology
  14. Cerebral adenosine A1 receptors are upregulated in rodent encephalitis
    Soumen Paul, Shivashankar Khanapur, Wytske Boersma‐van Ek, Jürgen W. A. Sijbesma, Kiichi Ishiwata, Philip H. Elsinga, Peter Meerlo, Janine Doorduin, Rudi Dierckx, Aren van Waarde · 2014 · NeuroImage
  15. La Enfermedad de Parkinson: Etiología, Tratamientos y Factores Preventivos
    F Hurtado, Melissa Andrea N. Cardenas, Fernando P. Cárdenas, Laura Andrea León · 2017 · Universitas Psychologica
  16. Impaired tissue barriers as potential therapeutic targets for Parkinson’s disease and amyotrophic lateral sclerosis
    Xin Fang · 2018 · Metabolic Brain Disease
  17. Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease
    Emmi K Saarinen, Tomi Kuusimäki, Kari Lindholm, Kalle J. Niemi, Emma A. Honkanen, Tommi Noponen, Marko Seppänen, Toni Ihalainen, Kirsi Murtomäki, Tuomas H. Mertsalmi et al. · 2024 · Annals of Neurology
  18. Modifiable risk factors associated with the risk of developing Parkinson's disease: a critical review
    Vítor Tumas, Marcelo Jhonatan Aureliano, Carlos Roberto de Mello Rieder, Artur Francisco Schumacher Schuh, Henrique Ballalai Ferraz, Vanderci Borges, Maria Carolina Soares, Dayany Leonel Boone, Carolina Candeias da Silva, Mariana Cavalcanti Costa et al. · 2025 · Arquivos de Neuro-Psiquiatria
  19. Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting
    Roberta Bonomo, Guido Cavaletti, Debra Jean Skene · 2020 · Expert Review of Neurotherapeutics
  20. Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson’s disease patients and healthy controls
    Chao Wang, Cheng Zhou, Tao Guo, Yeerfan Jiaerken, Siyu Yang, Xiaopei Xu, Ling Hu, Peiyu Huang, Xiaojun Xu, Minming Zhang · 2023 · BMC Medicine
  21. Dietary Variations in a Multiethnic Parkinson’s Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study
    Anna Sauerbier, Anette E. Schrag, Pablo Martínez‐Martín, Lynsey J. Hall, Miriam Parry, Laurie K. Mischley, Panagiotis Zis, К. Ray Chaudhuri · 2018 · Parkinson s Disease
  22. Clinical profile of Parkinson's disease in the Gumei community of Minhang district, Shanghai
    Kangyong Liu, Zhaohua Gu, Liang Dong, Liwei Shen, Yinyi Sun, Ting Zhang, Nan Shi, Qian Zhang, Wei Zhang, Meizhen Zhao et al. · 2014 · Clinics
  23. Caffeine treatment aggravates secondary degeneration after spinal cord injury
    Cheng-Chang Yang, I‐Ming Jou · 2015 · Brain Research
  24. Coffee, Caffeine and Cognition: a Benefit or Disadvantage?
    Jiří Patočka, Zdeňka Navrátilová, Ondřej Krejcar, Kamil Kuča · 2019 · Letters in Drug Design & Discovery
  25. Effects of chronic caffeine on patterns of brain blood flow and behavior throughout the sleep–wake cycle in freely behaving mice
    Kimiya R. Aframian, Dmitri Yousef Yengej, Sinifunanya E. Nwaobi, Shrayes Raman, Guido C. Faas, Andrew C. Charles · 2023 · PNAS Nexus
  26. Using caffeine as a chemical means to induce flow states
    Niklas Reich, Michael Mannino, Steven Kotler · 2024 · Neuroscience & Biobehavioral Reviews
  27. Beta2-Adrenergic Suppression of Neuroinflammation in Treatment of Parkinsonism, with Relevance for Neurodegenerative and Neoplastic Disorders
    Mario A. Inchiosa · 2024 · Biomedicines
  28. Do physical exercise and reading reduce the risk of Parkinson’s disease? a cross-sectional study on factors associated with Parkinson’s disease in elderly Chinese veterans
    Yongming Zou, JP Tan, Nan Li, JS Yang, Bao-cheng Yu, JM Yu, Yiming Zhao, Luning Wang · 2015 · Neuropsychiatric Disease and Treatment
  29. Potential new therapies against a toxic relationship: neuroinflammation and Parkinson’s disease
    Laís Soares Rodrigues, Juliane Fagotti, Adriano Targa, Ana Carolina D. Noseda, Jéssica L. Ilkiw, Ana Paula Chuproski, Flávia W. C. Dorieux, Patricia D. dos Santos, Marcelo M. S. Lima · 2019 · Behavioural Pharmacology
  30. Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease
    Mario H. Flores‐Torres, Xiaojing Peng, Sarah Jeanfavre, Clary B. Clish, Ying Wang, Marjorie L. McCullough, Brian C. Healy, Michael A. Schwarzschild, Kjetil Bjørnevik, Alberto Ascherio · 2025 · Movement Disorders
  31. Erectile Dysfunction Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study in Olmsted County
    Shemonti Hasan, Michelle M. Mielke, J. Eric Ahlskog, James H. Bower, Pierpaolo Turcano, Rodolfo Savica · 2019 · Parkinson s Disease
  32. Quantitative description of bond lengths alternation for caffeine−effects of ionization, proton-transfer, and noncovalent interaction
    Ewa D. Raczyńska, Julian Kurpiewski, Małgorzata Igielska, Beata Kamińska · 2020 · Computational and Theoretical Chemistry
  33. Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease
    Gabriel Torrealba Acosta, Eric Yu, Tanya Lobo-Prada, Javier Ruiz‐Martínez, Ana Gorostidi Pagola, Ziv Gan‐Or, Kenneth Carazo-Céspedes, Jean-François Trempe, Ignacio Fernandez Mata, Jaime Fornaguera Trías · 2021 · Frontiers in Neurology
  34. Epidemiologic Risk and Prevention and Interventions in Parkinson Disease: From a Nutrition-Based Perspective
    Fan Zhang, Yuxian Liu, Yun Zhu, Qiu-Yan Yu, Samwel Sylvester Msigwa, Zhi-Hai Zeng, Xiong Zhang, Hong-Mei Wu, Jian‐Hong Zhu · 2025 · Journal of Nutrition
  35. Xanthine: Synthetic Strategy And Biological Activity
    2021 · Biointerface Research in Applied Chemistry
  36. Prevention of Parkinson’s Disease: From Risk Factors to Early Interventions
    Ming Guan Ng, Brendan Jun Lam Chan, Rhun Yian Koh, Khuen Yen Ng, Soi Moi Chye · 2023 · CNS & Neurological Disorders - Drug Targets
  37. Screening and Targeting Risk Factors for Prodromal Synucleinopathy: Taking Steps toward a Prescriptive Multi-modal Framework
    Lee E. Neilson, Joseph F. Quinn, Miranda M. Lim · 2023 · Aging and Disease
  38. Role of neuron specific enolase as a biomarker in Parkinson’s disease
    Rajib Dutta · 2021 · Journal of Neuroscience and Neurological Disorders
  39. Association of coffee consumption and striatal volume in patients with Parkinson's disease and healthy controls
    Chao Wang, Cheng Zhou, Tao Guo, Yeerfan Jiaerken, Siyu Yang, Peiyu Huang, Xiaojun Xu, Minming Zhang · 2023 · CNS Neuroscience & Therapeutics
  40. Koffein, Schokolade und Adenosin A2A Rezeptorantagonisten in der Behandlung des Parkinson Syndroms
    Heinz Reichmann · 2022 · Fortschritte der Neurologie · Psychiatrie
  41. Use of Herbal Products/Alternative Medicines in Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease)
    Omar M. E. Abdel‐Salam · 2018 · Springer eBooks
  42. Parkinson’s Disease: Contemporary Concepts and Clinical Management
    Vanessa Carvalho, Carlota Vicente Cunha, João Massano · 2018 · Springer eBooks
  43. From Clinical to Basic Research: The Neuroprotective Effects and Mechanisms of Caffeine
    Lijing Wang, Linxi Wang · 2025 · Health and Metabolism
  44. Yerbamate Tea Consumption: A Protective Factor in Parkinson Disease
    Michel Sáenz‐Farret, Ana Marı́a Salinas-Martı́nez, Carlos Zúñiga‐Ramírez, Ignacio Amorín-Costábile, Ricardo Maiola, Koni Katerin Mejía-Rojas, Martha Sady Galeano, Carolina Velázquez, Gabriela Ruiz, Federico Eduardo Micheli · 2022 · Clinical Neuropharmacology
  45. Novel Metabolic Biomarkers and Therapeutic Strategies in Neurodegenerative Diseases
    Anurag Thapliyal, Shweta, Shashank Kumar Maurya · 2024 · Springer eBooks
  46. A cup of coffee a day keeps dyskinesia away?
    Peter G. Jenner · 2013 · Movement Disorders
  47. Caffeine and Neuroprotection in Parkinson’s Disease
    Filipe Brogueira Rodrigues, Daniel Caldeira, Joaquim José Ferreira, João Guilherme Costa · 2015 · Current topics in neurotoxicity
  48. The Association Between Low Levels of Serum Vitamin D and the Duration and Severity of Parkinson’s Disease
    Alijan Ahmadi Ahangar, Payam Saadat, Karimollah Hajian‐Tilaki, Gaffar Kiapasha · 2018 · Archives of Neuroscience
  49. Substance use disorders in the elderly
    Tylor J. Jilk, Martin S. Mumenthaler · 2020 · Elsevier eBooks
  50. Physiological basis of dietary prevention of perimenopausal disorders in the context of dietary habits associated with the consumption of water and beverages by women aged 45-65
    Joanna Sadowska, Zuzanna Remiszewska · 2014 · Menopause Review/Przegląd Menopauzalny
  51. Metabolomic Biomarkers in Parkinson’s Disease
    Yaping Shao, Xiaojiao Xu, Nanxing Wang, Guowang Xu, Weidong Le · 2021 · Neuromethods
  52. Does Caffeine Consumption Affect the Symptoms of Parkinson’s Disease? A Systematic Review of Clinical Trials
    Anita Reyhanifard, Sarvin Sanaie, Mojgan Mirghafourvand‬‬‬‬‬‬‬‬‬‬‬‬‬‬, Sama Rahnemayan, Arezoo Fathalizadeh, Ata Mahmoodpoor, Elnaz Faramarzi · 2021 · Archives of Neuroscience
  53. Coffee and the Brain: A Comprehensive Review of Its Neurological and Psychiatric Effects
    Varun Pareek, Saksham Shah, Beena Sharma, Susheel Kumar, Lokendra Kumar Sharma · 2024 · Journal of The Indian Academy of Geriatrics
  54. Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson’s Disease
    Xiaoxue Dong, Yilong Zheng, Evelyn Ting Ying Tan, Qiao Yang Sun, Bin Xiao, Eng-King Tan, Yun‐Cheng Wu, Zhidong Zhou · 2025 · International Journal of Molecular Sciences
  55. Complex liaisons moving forward the Parkinson’s disease? An appraisal
    Graziella Rubino · 2015 · Basal Ganglia
  56. Dietary Supplements for Obesity and the Metabolic Syndrome
    Kavita H. Poddar, Gerard E. Mullin, Lawrence Jay Cheskin · 2014 · Springer eBooks
  57. Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists
    Nicola Simola, Annalisa Pinna, Lucia Frau, Micaela Morelli · 2014 · Springer eBooks
  58. Gut Microbiota in Brain Development and Disorders of the CNS: Therapeutic Strategies Involving Dietary Modification, Pro- and Prebiotic Intervention, and Fecal Microbiota Transplantation (FMT) Therapy
    Bryan C. Tungland · 2018 · Elsevier eBooks
  59. Micronutrients and Parkinson’s Disease
    Shahrul Azmin, Rufaidah Md. Rani, Norlinah Mohamed Ibrahim · 2022 · Nutritional neurosciences
  60. Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists
    Nicola Simola, Annalisa Pinna, Lucia Frau, Giulia Costa, Jacopo Marongiu, Pathik Parekh, Marcello Serra, Micaela Morelli · 2022 · Springer eBooks
  61. Cigarette Smoking, nicotine and Parkinson’s disease: Controversies in clinical trials data and medical practice.
    A.A. Kesoyan., N.L. Arakelyan, D.A. Aloyan, A.A. Karapetyan, Hovhannes M. Manvelyan · 2022 · THE NEW ARMENIAN MEDICAL JOURNAL
  62. Design principles of ROS dynamic networks relevant to precision therapies for age-related diseases
    Alexey N. Kolodkin, Raju Prasad Sharma, Anna Maria Colangelo, Andrew Ignatenko, Francesca Martorana, Danyel G. J. Jennen, Jacob J. Briedé, Nathan Ryan Brady, Matteo Barberis, Thierry D.G.A. Mondeel et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  63. Processed coffee alleviates DSS-induced colitis in mice
    Bernd L. Fiebich, Amaya García de Vinuesa, Gonzalo Sánchez‐Duffhues, Juan Antonio Collado, Thorsten Rose, J. Menthe, Eduardo Muñóz · 2013 · Functional Foods in Health and Disease
  64. Adenosine A2A Receptor-Mediated Control of Non-Motor Functions in Parkinson’s Disease
    Rui Daniel Prediger, Filipe Carvalho MATHEUS, Paulo Alexandre de Oliveira, Daniel Rial, Morgana Moretti, Ana Cristina Guerra Souza, Aderbal S. Aguiar, Rodrigo Antunes Cunha · 2015 · Current topics in neurotoxicity
  65. Role of Adenosine A2A Receptors in the Control of Neuroinflammation—Relevance for Parkinson’s Disease
    Catarina A. Gomes, Jimmy George, Jiang‐Fan Chen, Rodrigo Antunes Cunha · 2015 · Current topics in neurotoxicity
  66. Effect of Coffee, Tobacco, and Alcohol on Parkinson’s Disease
    Wongi Seol, Hye Jung Kim, Ilhong Son · 2021 · Journal of the Korean Neurological Association
  67. Therapeutic and Diagnostic Agents for Parkinson's Disease
    Ola M. Ghoneim, Raymond G. Booth · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  68. Natural Stimulants
    2015 · CRC Press eBooks
  69. Potential Neuromodulatory Profile of Phytocompounds in Brain Disorders
    Luigia Trabace · 2017 · MDPI eBooks
  70. Parkinson’s Disease
    Robert Kachko, Pina LoGiudice · 2020 · Elsevier eBooks
  71. Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists
    Nicola Simola, Annalisa Pinna, Lucia Frau, Giulia Costa, Jacopo Marongiu, Pathik Parekh, Marcello Serra, Micaela Morelli · 2021 · Springer eBooks
  72. Association of Coffee Consumption and Striatal Dopamine Transporter Binding in Patients with Parkinson’s Disease and Healthy Controls
    Chao Wang, Cheng Zhou, Tao Guo, Yeerfan Jiaerken, Siyu Yang, Peiyu Huang, Xiaojun Xu, Minming Zhang · 2022 · Research Square
  73. Instituto de pesquisa café e saúde: Prevenção de doenças e melhora da qualidade de vida
    Rodrigo Antunes Cunha, Francieli Rohden, Diogo Onofre Souza · 2024 · Research Society and Development
  74. Caffeine Consumption and Interaction with ADORA2A, CYP1A2 and NOS1 Variants Do Not Influence Age at Onset of Machado-Joseph Disease
    Ana Carolina Martins, Jordânia dos Santos Pinheiro, Luciana Szinwelski, Eduardo Rockenbach Cidade, Danilo Fernando Santin, Laura Damke Proença, Bruna Almeida Araújo, Maria Luiza Saraiva Pereira, Laura Bannach Jardim · 2024 · The Cerebellum
  75. Non-pharmacologic Interventions in Gut PD
    George Triadafilopoulos · 2024 · Springer eBooks
  76. Cacoa Prevents Degeneration of Dopamine Neurons and Motor Impairment Caused by Rotenone
    Marwa El-Sayed El-Shamarka, Omar M. E. Abdel‐Salam, Nermeen Shaffie · 2025 · International Journal of Applied Sciences & Development
  77. Coffee and Parkinson’s Disease
    Katarzyna Śmiłowska, Natalia Szejko, Vanessa Carvalho · 2025 · Springer eBooks
  78. Additional file 1 of Occupational pesticide exposure and the risk of death in patients with Parkinson’s disease: an observational study in southern Brazil
    Schneider Medeiros, Márcio, P. Reddy, Sumanth, P. Socal, Mariana, Artur Francisco Schumacher‐Schuh, Mello Rieder, Carlos Roberto · 2020 · Figshare
  79. Additional file 1 of Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson’s disease patients and healthy controls
    Wang, Chao, Zhou, Cheng, Guo, Tao, Yeerfan Jiaerken, Yang, Siyu, Xu, Xiaopei, Hu, Ling, Huang, Peiyu, Xu, Xiaojun, Zhang, Minming · 2023 · Figshare
  80. Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study
    Chengsheng Ju, Kiyoshi Kubota, Xi Xiong, Tsugumichi Sato, Camille Carroll, Anette E. Schrag, Li Wei, Thomas Foltynie · 2026 · Parkinsonism & Related Disorders
  81. EARLY-ALS: A Multicentre Study on Presymptomatic and Prodromal Amyotrophic Lateral Sclerosis
    Isabell Cordts, Ana Galhoz, Laura Tzeplaeff, Anne Gründel, Florian Kohlmayer, Andreas Schwersenz, Ines Marschalkowski, Bogdan Bjelica, Verena Panitz, Christian Schulze et al. · 2026 · medRxiv
  82. Bases neuro-fonctionnelles des troubles de l’impulsivité dans la maladie de Parkinson
    Garance M. Meyer · 2022 · theses.fr (ABES)
  83. Parkinson-Krankheit – Klinischer Überblick und Bedeutung für die Wirbelsäulenmedizin
    Daniel Charissé, Simon Baudrexel · 2026 · Die Wirbelsäule
  84. KAFEİNİN PSİKOFARMAKOLOJİK ETKİLERİ: NÖROPROTEKTİF KULLANIMA İLİŞKİN ÇIKARIMLAR
    Meryem Nezlioğlu Nezlioğlu, Ayşe Kübra Karaboğa Arslan · 2026 · Ankara Universitesi Eczacilik Fakultesi Dergisi
  85. EARLY-ALS: a multicentre study on prodromal amyotrophic lateral sclerosis
    Isabell Cordts, Ana Galhoz, Laura Tzeplaeff, Anne Gründel, Florian Kohlmayer, Andreas Schwersenz, Ines Marschalkowski, Bogdan Bjelica, Verena Panitz, Christian Schulze et al. · 2026 · EBioMedicine